In ₹ Crore except Per Share Latest Annual | ERIS FY26 | MANKIND FY26 | AJANTPHARM FY26 | TORNTPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 29.96× | 48.46× | 41.88× | 77.05× | 48.46× -38% | |
| P/B | ◆ 4.83× | 5.60× | 9.80× | 9.48× | 9.48× -49% | |
| EV/EBITDA | ◆ 18.80× | 26.84× | 31.49× | 39.37× | 31.49× -40% | |
| Market Cap | ₹18,808 Cr | ₹92,715 Cr | ₹44,374 Cr | ₹1.67L Cr | ₹92,715 Cr -80% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 22.92% | 17.73% | 13.37% | 13.27% | 13.37% +71% | |
| Revenue CAGR 5Y | ◆ 20.89% | — | 13.54% | 11.80% | 12.67% +65% | |
| Net Income CAGR 3Y | 20.06% | 13.96% | ◆ 21.55% | 19.75% | 19.75% +2% | |
| Revenue YoY (latest Q) | 12.97% | 12.89% | 24.82% | ◆ 54.85% | 24.82% -48% | |
| Net Income YoY (latest Q) | 14.56% | 29.12% | ◆ 30.89% | 3.28% | 29.12% -50% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 35.79% | 25.34% | 25.58% | 32.61% | 25.58% +40% | |
| Net Income Margin | ◆ 20.69% | 13.57% | 19.37% | 15.29% | 15.29% +35% | |
| Return on Common Equity | 15.90% | 11.55% | ◆ 23.33% | 12.30% | 12.30% +29% | |
| Return on Capital Employed | 15.90% | 12.66% | ◆ 25.78% | 9.56% | 12.66% +26% | |
| Return on Assets | 8.79% | 6.90% | ◆ 17.16% | 4.82% | 6.90% +27% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.59× | 0.38× | ◆ 0.05× | 0.84× | 0.38× +55% | |
| Interest Coverage | 4.36× | 4.27× | ◆ 75.83× | 8.94× | 8.94× -51% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹3,129 Cr | ₹14,278 Cr | ₹5,453 Cr | ₹13,980 Cr | ₹13,980 Cr -78% | |
| Net Income | ₹648 Cr | ₹1,938 Cr | ₹1,056 Cr | ₹2,138 Cr | ₹1,938 Cr -67% | |
| Total Assets | ₹7,366 Cr | ₹28,080 Cr | ₹6,155 Cr | ₹44,312 Cr | ₹28,080 Cr -74% | |
| EPS | ₹45.33 | ₹46.35 | ₹84.53 | ₹63.92 | ₹63.92 -29% | |
| Book Value per Share | ₹281.28 | ₹401.19 | ₹361.16 | ₹519.56 | ₹401.19 -30% | |